{"groups":[{"description":"Cohort 1: Participants received 25 mg Azacitidine sub-cutaneously, and 200 mg/m2 Temozolomide orally; both once a day on Days 1 - 5 of a 28-day cycle.","id":"FG000","title":"Azacitidine 25mg"},{"description":"Cohort 2: Participants received 50 mg Azacitidine sub-cutaneously, and 200 mg/m\\^2 Temozolomide orally; both once a day on Days 1 - 5 of a 28-day cycle.","id":"FG001","title":"Azacitidine 50 mg"},{"description":"Cohort 3: Participants received 75 mg Azacitidine sub-cutaneously, and 200 mg/m\\^2 Temozolomide orally; both once a day on Days 1 - 5 of a 28-day cycle.","id":"FG002","title":"Azacitidine 75 mg"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Dose Level 1: Azacitidine 25mg"},{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"0"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Dose Level 2: Azacitidine 50 mg"},{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"17"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"17"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Dose Level 3: Azacitidine 75mg"}],"preAssignmentDetails":"27 participants signed a consent form and four were determined to be ineligible, resulting in 23 assigned to treatment."}